| Title |
Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
|
|---|---|
| Published in |
Cancer Immunology, Immunotherapy, April 2008
|
| DOI | 10.1007/s00262-008-0509-2 |
| Pubmed ID | |
| Authors |
Asna Amin, Linda C. Benavides, Jarrod P. Holmes, Jeremy D. Gates, Mark G. Carmichael, Matthew T. Hueman, Elizabeth A. Mittendorf, Catherine E. Storrer, Yusuf H. Jama, Dianna Craig, Alex Stojadinovic, Sathibalan Ponniah, George E. Peoples |
| Abstract |
E75, a HER2/neu immunogenic peptide, is expressed in breast cancer (BCa). We have performed clinical trials of E75 + GM-CSF vaccine in disease-free, node-positive and node-negative BCa patients at high recurrence risk and recurrences were noted in both control and vaccine groups. |
Mendeley readers
The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 3% |
| Chile | 1 | 3% |
| Spain | 1 | 3% |
| Unknown | 32 | 91% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 9 | 26% |
| Other | 4 | 11% |
| Professor | 4 | 11% |
| Student > Bachelor | 4 | 11% |
| Student > Doctoral Student | 3 | 9% |
| Other | 8 | 23% |
| Unknown | 3 | 9% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 34% |
| Agricultural and Biological Sciences | 8 | 23% |
| Biochemistry, Genetics and Molecular Biology | 3 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Business, Management and Accounting | 2 | 6% |
| Other | 3 | 9% |
| Unknown | 5 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 November 2020.
All research outputs
#4,697,128
of 22,790,780 outputs
Outputs from Cancer Immunology, Immunotherapy
#504
of 2,881 outputs
Outputs of similar age
#15,788
of 81,919 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#7
of 26 outputs
Altmetric has tracked 22,790,780 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,881 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 81,919 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.